Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPR-101 + Metronidazole for Prevention of BV Recurrence
NCT07483671Phase 2Not yet recruiting
- Sponsor
- Chengdu Syncor Pharmaceutical
- Start
- Apr 2026
- Primary completion
- Jan 2027
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BPR-101 in bacterial vaginosis (BV) (2 arms), sponsored by Chengdu Syncor Pharmaceutical. Primary endpoint: Recurrence rate of Bacterial Vaginosis at Day 90. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
BPR-101
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on NCT07483671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07483671.